Deep vein thrombosis cost-effectiveness of therapy
Editor(s)-In-Chief: The APEX Trial Investigators, C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2] Ujjwal Rastogi, MBBS [3]; Kashish Goel, M.D.; Assistant Editor(s)-In-Chief: Justine Cadet
|
Deep vein thrombosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Cost-Effectiveness of Therapy |
|
Case Studies |
|
Deep vein thrombosis cost-effectiveness of therapy On the Web |
|
Deep vein thrombosis cost-effectiveness of therapy in the news |
|
Blogs on Deep vein thrombosis cost-effectiveness of therapy</small> |
|
Risk calculators and risk factors for Deep vein thrombosis cost-effectiveness of therapy |
Cost-Effectiveness of Therapy
In United States, deep vein thrombosis DVT and pulmonary embolism PE costs are[1]:
- Initial hospitalization, average more than $9,800 and $14,000 respectively;
- Rehospitalization (over half of which occurs within 90 days) costs average more than $11,800 and $14,700, respectively.
Thus, after major orthopedic surgery, the use of effective VTE prevention strategies can reduce this economic burden.
On the basis of Canadian cost-effectiveness guidelines in the early 1990s, there is moderate to strong evidence to adopt enoxaparin prophylaxis against DVT after total hip replacement.[2]
References
- ↑ Spyropoulos AC, Lin J (2007). "Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations.". J Manag Care Pharm 13 (6): 475-86. PMID 17672809.
- ↑ O'Brien BJ, Anderson DR, Goeree R (April 1994). "Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement". CMAJ 150 (7): 1083–90. PMID 8137188.
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
